Search

Displaying results 4261 - 4270 of 7284 in total
  1. Drug

    Oxymorphone

    go.drugbank.com/drugs/DB01192
    ApprovedVet approved

    On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation.

  2. Drug

    Lucinactant

    go.drugbank.com/drugs/DB04897
    Approved

    FDA approved on March 6, 2012. … Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use.

  3. Drug

    Rice bran oil

    go.drugbank.com/drugs/DB11293
    ApprovedInvestigational

    Rice bran oil is classified as an indirect additive used in food contact substances by the FDA.

    Categories: Complex Mixtures
  4. Drug

    Hydrogenated soybean oil

    go.drugbank.com/drugs/DB11302
    Approved

    According to the FDA, hydrogenated soybean oil is generally recognized as safe (GRAS) food substance. … Extracted from the seeds of the soybean (Glycine soja), hydrogenated soybean oil is a major food fat used in the production of margarine, shortening, and salad and cooking oils.

  5. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    ], a CFTR potentiator, for the treatment of patients with responsive CFTR mutations. … [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor

  6. Drug

    Enmetazobactam

    go.drugbank.com/drugs/DB18716
    ApprovedInvestigational

    Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor. … [A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections.

  7. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). … The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).

  8. Drug

    Obecabtagene autoleucel

    go.drugbank.com/drugs/DB17362
    ApprovedInvestigational

    Obecabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with a fast off-rate binding profile for CD19. … [A265050] On November 8, 2024, obecabtagene autoleucel was approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

    Synonyms: A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING O, AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OBTAINED BY APHERESIS TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING
  9. Drug

    Perboric acid

    go.drugbank.com/drugs/DB13235
    Approved

    Perboric acid is mainly found in its salt form of sodium perborate and it can be found as a monohydrate or tetrahydrate. … [L1113] By the FDA, sodium perborate is approved as an ointment for the protection of poison ivy dermatitis.[L2764]

  10. Drug

    Ferrous sulfate anhydrous

    go.drugbank.com/drugs/DB13257
    ApprovedInvestigational

    [A190804] This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells. … Iron deficiency anemia is a large public health concern worldwide, especially in young children, infants, and women of childbearing age.

    Mixtures: Phytofortis + Calcium A-D, Hormodausse Plus Calc Et D Tab